Petros Grivas· @PGrivasMDPhD · X·· 2 天前评分70
正文 · 机器翻译
Jens 的精彩演讲介绍了 KN866 试验的结果；与 NIAGARA 相比，该试验未达到主要终点。围手术期 EV-pembro 是 MIBC 的标准治疗（SOC），明天的 VOLGA 试验值得期待！ @myESMO #ESMO26 #ESMOAmbassadors @OncoAlert @Uromigos @shilpaonc @AndreaNecchi
661 浏览 · 21 赞 · 9 转发 · 0 回复
会议摘要
LBA2按 Presidential Symposium I 对上
Perioperative durvalumab with or without tremelimumab plus neoadjuvant enfortumab vedotin in muscle-invasive bladder cancer: Results from the phase 3 VOLGA trial
https://esmocongress.esmo.orgVOLGA
https://esmocongress.esmo.orgFull house for Bladder/RCC updates first with #KN866 #ESMO26 Gem/cis in MIBC + placebo or pembro (➖) study & less relevance in the era of EVP SOC Vs similar trial NIAGARA was ➕ pCR 44.4% vs 35.8% EFS & OS not significant We wait #VOLGA tomorrow for more in this space在 X 查看被引用的帖子
来源：Petros Grivas · x.com